title: Methylene blue.
abstract: Methylene blue finds its major utilization in toxicology in the treatment of methemoglobinemia at a dose of 1 to 2 mg/kg intravenously. By interacting with methemoglobin and the erythrocyte's enzyme systems to reduce back to hemoglobin, methylene blue is a generally safe drug with dose-related hemolytic effects. People with G-6-PD deficiency, along with patients exposed to aniline dyes and dapsone, may present with special risks in the treatment of methemoglobinemia.
authors.affiliation: Department of Pediatrics, Rush Medical College, Chicago, IL, USA.
authors.forename: Jack
authors.initials: J
authors.lastname: Clifton
authors.forename: Jerrold B
authors.initials: JB
authors.lastname: Leikin
mesh_terms: D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D007408:Intestinal Absorption; D008708:Methemoglobinemia / Q000188:drug therapy; D008751:Methylene Blue / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D004791:Enzyme Inhibitors; D008751:Methylene Blue